{"doi":"10.3390/jcm11123349","title":"Changes of Acute Kidney Injury Epidemiology during the COVID-19 Pandemic: A Retrospective Cohort Study","abstract":"<jats:p>To evaluate the impact of the Coronavirus Disease-19 (COVID-19) pandemic on the epidemiology of acute kidney injury (AKI) in hospitalized patients, we performed a retrospective cohort study comparing data of patients hospitalized from January 2016 to December 2019 (pre-COVID-19 period) and from January to December 2020 (COVID-19 period, including both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative and positive patients). AKI was classified by evaluating the kinetics of creatinine levels. A total of 51,681 patients during the pre-COVID-19 period and 10,062 during the COVID-19 period (9026 SARS-CoV-2-negative and 1036 SARS-CoV-2-positive) were analyzed. Patients admitted in the COVID-19 period were significantly older, with a higher prevalence of males. In-hospital AKI incidence was 31.7% during the COVID-19 period (30.5% in SARS-CoV-2-negative patients and 42.2% in SARS-CoV-2-positive ones) as compared to 25.9% during the pre-COVID-19 period (p &lt; 0.0001). In the multivariate analysis, AKI development was independently associated with both SARS-CoV-2 infection and admission period. Moreover, evaluating the pre-admission estimated glomerular filtration rate (eGFR) we found that during the COVID-19 period, there was an increase in AKI stage 2–3 incidence both in patients with pre-admission eGFR &lt; 60 mL/min/1.73 m2 and in those with eGFR ≥ 60 mL/min/1.73 m2 (“de novo” AKI). Similarly, clinical outcomes evaluated as intensive care unit admission, length of hospital stay, and mortality were significantly worse in patients admitted in the COVID-19 period. Additionally, in this case, the mortality was independently correlated with the admission during the COVID-19 period and SARS-CoV-2 infection. In conclusion, we found that during the COVID-19 pandemic, in-hospital AKI epidemiology has changed, not only for patients affected by COVID-19. These modifications underline the necessity to rethink AKI management during health emergencies.</jats:p>","journal":"Journal of Clinical Medicine","year":2022,"id":641007,"datarank":0.47032413238937254,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"self_citation_contribution":0.47032413238937254,"citation_network_contribution":0.0,"self_endowment_contribution":0.47032413238937254,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1666307,"name":"Elisa Russo","orcid":"0000-0003-1279-3178","position":1,"is_corresponding":false},{"id":1666308,"name":"Daniela Picciotto","orcid":null,"position":2,"is_corresponding":false},{"id":1666309,"name":"Francesca Cappadona","orcid":null,"position":3,"is_corresponding":false},{"id":1666311,"name":"Yuri Battaglia","orcid":"0000-0003-3947-1814","position":4,"is_corresponding":false},{"id":1666312,"name":"Giovanni Battista Traverso","orcid":null,"position":5,"is_corresponding":false},{"id":1545734,"name":"Francesca Viazzi","orcid":"0000-0003-4219-7043","position":6,"is_corresponding":false},{"id":399541,"name":"Pasquale Esposito","orcid":"0000-0002-0834-5586","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Changes of Acute Kidney Injury Epidemiology during the COVID-19 Pandemic: A Retrospective Cohort Study","abstract":"<jats:p>To evaluate the impact of the Coronavirus Disease-19 (COVID-19) pandemic on the epidemiology of acute kidney injury (AKI) in hospitalized patients, we performed a retrospective cohort study comparing data of patients hospitalized from January 2016 to December 2019 (pre-COVID-19 period) and from January to December 2020 (COVID-19 period, including both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative and positive patients). AKI was classified by evaluating the kinetics of creatinine levels. A total of 51,681 patients during the pre-COVID-19 period and 10,062 during the COVID-19 period (9026 SARS-CoV-2-negative and 1036 SARS-CoV-2-positive) were analyzed. Patients admitted in the COVID-19 period were significantly older, with a higher prevalence of males. In-hospital AKI incidence was 31.7% during the COVID-19 period (30.5% in SARS-CoV-2-negative patients and 42.2% in SARS-CoV-2-positive ones) as compared to 25.9% during the pre-COVID-19 period (p &lt; 0.0001). In the multivariate analysis, AKI development was independently associated with both SARS-CoV-2 infection and admission period. Moreover, evaluating the pre-admission estimated glomerular filtration rate (eGFR) we found that during the COVID-19 period, there was an increase in AKI stage 2–3 incidence both in patients with pre-admission eGFR &lt; 60 mL/min/1.73 m2 and in those with eGFR ≥ 60 mL/min/1.73 m2 (“de novo” AKI). Similarly, clinical outcomes evaluated as intensive care unit admission, length of hospital stay, and mortality were significantly worse in patients admitted in the COVID-19 period. Additionally, in this case, the mortality was independently correlated with the admission during the COVID-19 period and SARS-CoV-2 infection. In conclusion, we found that during the COVID-19 pandemic, in-hospital AKI epidemiology has changed, not only for patients affected by COVID-19. These modifications underline the necessity to rethink AKI management during health emergencies.</jats:p>","is_dataset_classified":null,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35743418","pmcid":"PMC9225342","openalex_id":"https://openalex.org/W4281634206","authors":[],"funders":[],"total_grants":0,"fwci":2.0461,"citation_percentile":0.89202537,"influential_citations":0,"citation_trend":[{"year":2022,"count":5},{"year":2023,"count":8},{"year":2024,"count":6},{"year":2025,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2077-0383/11/12/3349/pdf?version=1654865088","host_type":"journal"},{"url":"https://www.mdpi.com/2077-0383/11/12/3349/pdf?version=1654865088","host_type":"publisher"},{"url":"https://www.mdpi.com/2077-0383/11/12/3349/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/jcm11123349","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35743418","host_type":"repository"},{"url":"https://doaj.org/article/123c6383aa714a05b99e791a8fab5b30","host_type":"repository"},{"url":"http://hdl.handle.net/11567/1093879","host_type":"repository"},{"url":"https://www.mdpi.com/2077-0383/11/12/3349","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/jcm11123349","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9225342","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9225342","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9225342?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["COVID-19 and healthcare impacts","COVID-19 Clinical Research Studies","Acute Kidney Injury Research"],"mesh_terms":[],"keywords":["Medicine","Acute kidney injury","Retrospective cohort study","Incidence (geometry)","Epidemiology","Coronavirus disease 2019 (COVID-19)","Internal medicine","Intensive care unit","Pandemic","Cohort","Renal function","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Emergency medicine","Disease","Infectious disease (medical specialty)","Mortality","Hospitalization","Covid-19","Sars-cov-2"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T15:19:40.391415Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}